Connect with us

Published

on

Weight loss has always been big business, but it’s exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs.

In the first half of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. That’s after quarterly prescriptions for those types of GLP-1 treatments, which mimic a hormone in the gut to suppress a person’s appetite, increased 300% between early 2020 and the end of last year.

But as consumers and businesses pour more money and resources into tackling the obesity epidemic, which costs the U.S. more than $170 billion a year, drug developers aren’t alone in coming up with innovative solutions.

Signos, a five-year-old startup, is taking an approach that doesn’t involve pills.

The company is using off-the-shelf continuous glucose monitors, or CGMs, and providing real-time diet and exercise recommendations based on an individual’s readings. CGMs are small sensors worn on the upper arm that track glucose levels, primarily for people with diabetes. The information is wirelessly sent to a smartphone, allowing the user to better prevent emergencies.

Signos uses CGMs built by Dexcom. The startup has its own app that shows users how their body responds to specific foods, what causes their glucose to spike and when they should exercise to get the best results for weight loss.

On Tuesday, Signos said it closed a $20 million funding round led by Cheyenne Ventures and GV, formerly known as Google Ventures. Dexcom Ventures also contributed to the financing. Signos said it will use the fresh capital to continue its research into metabolic health and to expand its team, which is currently around 45 people.

“Whether you have five pounds to lose or 100, we want to make sure we’re able to help everybody,” Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, told CNBC in an interview. 

Customers who sign up for Signos can choose a one-month, three-month or six-month plan. With the half-year plan, users pay $143 a month, which includes all of the pricey CGMs they’ll need during that time. The company declined to share specific details about how many people are currently using its platform.

Fouladgar-Mercer said the long timelines are designed to attract users who are serious about their weight-loss journey. Additionally, the sensors themselves have a long wear time. The Dexcom G6 and G7, the latest devices, can measure glucose for up to 10 days. Signos currently supports the G6 and will soon work with the G7 as well.

Fouladgar-Mercer said Signos is using Dexcom’s CGMs as part of a clinical study approved by an institutional review board designated by the U.S. Food and Drug Administration to monitor biomedical research involving real people. 

Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. He trained as an athlete and played hockey in college, but he said he noticed how food often affected him differently from the way it affected his teammates.

He said he always felt that, in an effort to understand an individual’s metabolism, there was a “critical component” missing, and it had been nagging at him for 30 years.

Signos helps users understand the right decision to make in the moment, but they can go “behind the scenes” and learn as much about the science as they’d like, Fouladgar-Mercer said. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. 

“Once they trust the system works and they understand the methodology, they can just follow the really quick, here’s what I do, here’s what I do, here’s what I do,” Fouladgar-Mercer said. “And that’s how you get behavioral change.”

Though Dexcom primarily develops its CGMs for patients with diabetes, the company is also working toward broader applications. For instance, next year it’s releasing a new product meant for people who aren’t taking insulin. Similarly, Abbott Laboratories, which dominates the global CGM market, is hoping to bring its first consumer-facing CGM, called Lingo, to the U.S. next year, adding personalized coaching with recommendations about diet, sleep and exercise.

Fouladgar-Mercer said Signos has more data points than “anybody does in the world for non-diabetics.” He added that since the company built its first product almost five years ago, it’s been able to focus on fine-tuning its technology. 

“I don’t want to incorrectly set expectations,” Fouladgar-Mercer said. “I think a lot of times, it’s like, ‘Oh, lost X pounds in X days.’ That’s not what we’re trying to accomplish. It’s really, how do we put you on a sustainable journey? And that journey is not going to be done in two or three days.”

Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments. Novo Nordisk’s share price has quadrupled since 2018, and the company is now the most valuable in Europe.  

Fouladgar-Mercer said GLP-1 drugs are a “powerful tool” that can help people jump-start weight loss, but it can be challenging to keep weight off if they stop taking the medication. Platforms such as Signos can help to reinforce and maintain a healthier lifestyle over time, he said.

Ultimately, he said, he wants people to use Signos to learn how to make better choices that work best for their bodies. 

Signos, Fouladgar-Mercer said, can use technology and data “to drive behavioral change, and then wrap that all in a system that really is focused on driving and solving this biggest problem we have in America, which is weight.”

WATCH: Novo Nordisk stops Ozempic trial early after signs of success

Continue Reading

Technology

Navan sets price range for IPO, expects market cap of up to $6.5 billion

Published

on

By

Navan sets price range for IPO, expects market cap of up to .5 billion

FILE PHOTO: Ariel Cohen during a panel at DLD Munich Conference 2020, Europe’s big innovation conference, Alte Kongresshalle, Munich.

Picture Alliance for DLD | Hubert Burda Media | AP

Navan, a developer of corporate travel and expense software, expects its market cap to be as high as $6.5 billion in its IPO, according to an updated regulatory filing on Friday.

The company said it anticipates selling shares at $24 to $26 each. Its valuation in that range would be about $3 billion less than where private investors valued Navan in 2022, when the company announced a $300 million funding round.

CoreWeave, Circle and Figma have led a resurgence in tech IPOs in 2025 after a drought that lasted about three years. Navan filed its original prospectus on Sept. 19, with plans to trade on the Nasdaq under the ticker symbol “NAVN.”

Last week, the U.S. government entered a shutdown that has substantially reduced operations inside of agencies including the SEC. In August, the agency said its electronic filing system, EDGAR, “is operated pursuant to a contract and thus will remain fully functional as long as funding for the contractor remains available through permitted means.”

Cerebras, which makes artificial intelligence chips, withdrew its registration for an IPO days after the shutdown began.

Navan CEO Ariel Cohen and technology chief Ilan Twig started the company under the name TripActions in 2015. It’s based in Palo Alto, California, and had around 3,400 employees at the end of July.

For the July quarter, Navan recorded a $38.6 million net loss on $172 million in revenue, which was up about 29% year over year. Competitors include Expensify, Oracle and SAP. Expensify stock closed at $1.64on Friday, down from its $27 IPO price in 2021.

Navan ranked 39th on CNBC’s 2025 Disruptor 50 list, after also appearing in 2024.

WATCH: Brex CEO on Navan partnership

We developed 'best in class' enterprise travel expense solution, says Brex CEO on Navan partnership

Continue Reading

Technology

Tech megacaps lose $770 billion in value as Nasdaq suffers steepest drop since April

Published

on

By

Tech megacaps lose 0 billion in value as Nasdaq suffers steepest drop since April

Jensen Huang, CEO of Nvidia, speaking with CNBC’s Jim Cramer during a CNBC Investing Club with Jim Cramer event at the New York Stock Exchange on Oct. 7th, 2025.

Kevin Stankiewicz | CNBC

Shares of Amazon, Nvidia and Tesla each dropped around 5% on Friday, as tech’s megacaps lost $770 billion in market cap, following President Donald Trump’s threats for increased tariffs on Chinese goods.

With tech’s trillion-dollar companies occupying an increasingly large slice of the U.S. market, their declines send the Nasdaq down 3.6% and the S&P 500 down 2.7%. For both indexes, it was the worst day since April, when Trump said he would slap “reciprocal” duties on U.S. trading partners.

After market close on Friday, Trump declared in a social media post that the U.S. would impose a 100% tariff on China and on Nov. 1 it would apply export controls “on any and all critical software.”

Amazon, Nvidia and Tesla all slipped about 2% in extended trading following the post.

The president’s latest threats are disrupting, at least briefly, what had been a sustained rally in tech, built on hundreds of billions of dollars in planned spending on artificial intelligence infrastructure.

Read more CNBC tech news

In late September, Nvidia, which makes graphics processing units for training AI models, became the first company to reach a market cap of $4.5 trillion. Nvidia alone saw its market capitalization decline by nearly $229 billion on Friday.

OpenAI counts on Nvidia’s GPUs from a series of cloud suppliers, including Microsoft. OpenAI is only seeing rising demand.

In September it introduced the Sora 2 video creation app, and this week the company said the ChatGPT assistant now boasts over 800 million weekly users. But Microsoft must buy infrastructure to operate its cloud data centers. Microsoft’s market cap dropped by $85 billion on Friday.

The sell-off wiped out Amazon’s gains for the year. That stock is now down 2% so far in 2025. It competes with Microsoft to rent out GPUs from its cloud data centers, but it doesn’t have major business with OpenAI. The online retailer is now worth $121 billion less than it was on Thursday.

“There continues to be a lot of noise about the impact that tariffs will have on retail prices and consumption,” Amazon CEO Andy Jassy told analysts in July. “Much of it thus far has been wrong and misreported. As we said before, it’s impossible to know what will happen.”

Tesla, which introduced lower-priced vehicles on Tuesday, saw its market capitalization sink by $71 billion.

The automaker reports third-quarter results on Oct. 22, with Microsoft earnings scheduled for the following week. Nvidia reports in November.

Google parent Alphabet and Facebook owner Meta fell 2% and almost 4%, respectively.

WATCH: Pres. Trump: Calculating massive increase of tariffs on Chinese products into U.S.

Pres. Trump: Calculating massive increase of tariffs on Chinese products into U.S.

Continue Reading

Technology

Govini, a defense tech startup taking on Palantir, hits $100 million in annual recurring revenue

Published

on

By

Govini, a defense tech startup taking on Palantir, hits 0 million in annual recurring revenue

Govini, a defense tech software startup taking on the likes of Palantir, has blown past $100 million in annual recurring revenue, the company announced Friday.

“We’re growing faster than 100% in a three-year CAGR, and I expect that next year we’ll continue to do the same,” CEO Tara Murphy Dougherty told CNBC’s Morgan Brennan in an interview. With how “big this market is, we can keep growing for a long, long time, and that’s really exciting.”

CAGR stands for compound annual growth rate, a measurement of the rate of return.

The Arlington, Virginia-based company also announced a $150 million growth investment from Bain Capital. It plans to use the money to expand its team and product offering to satisfy growing security demands.

In recent years, venture capitalists have poured more money into defense tech startups like Govini to satisfy heightened national security concerns and modernize the military as global conflict ensues.

The group, which includes unicorns like Palmer Luckey’s Anduril, Shield AI and artificial intelligence beneficiary Palantir, is taking on legacy giants such as Boeing, Lockheed Martin and Northrop Grumman, that have long leaned on contracts from the Pentagon.

Read more CNBC tech news

Dougherty, who previously worked at Palantir, said she hopes the company can seize a “vertical slice” of the defense technology space.

The 14-year-old Govini has already secured a string of big wins in recent years, including an over $900-million U.S. government contract and deals with the Department of War.

Govini is known for its flagship AI software Ark, which it says can help modernize the military’s defense tech supply chain by better managing product lifecycles as military needs grow more sophisticated.

“If the United States can get this acquisition system right, it can actually be a decisive advantage for us,” Dougherty said.

Looking ahead, Dougherty told CNBC that she anticipates some setbacks from the government shutdown.

Navy customers could be particularly hard hit, and that could put the U.S. at a major disadvantage.

While the U.S. is maintaining its AI dominance, China is outpacing its shipbuilding capacity and that needs to be taken “very seriously,” she added.

Continue Reading

Trending